GenSight Biologics
Paris, France · Biopharma, Biotechnology, Health Care
GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering
Key facts
- Headquarters
- Paris, France
- Employees
- 26
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- gensight-biologics.com
- Company page
Recent activity at GenSight Biologics
- : GenSight Biologics has successfully completed a fundraising of €1 million, supported by existing shareholders.
- : GenSight Biologics raises nearly €1.7 million in a successful funding round led by Heights Capital, Invus, and UPMC Enterprises to advance its gene therapies.
- : GenSight Biologics has successfully raised nearly €2 million from existing shareholders Invus and Alumni Capital to advance its gene therapy programs.
- : GenSight Biologics raises approximately EUR 500,000 through a capital increase from an existing shareholder, enhancing its operational roadmap. This comes after a prior financing of EUR 4 million announced earlier.
- : GenSight Biologics Formulates New Manufacturing Partnership with Catalent to Enhance LUMEVOQ Production.
- : GenSight Biologics Publishes 5-Year Outcomes for LUMEVOQ® Gene Therapy in LHON Patients
- : GenSight Biologics appoints Laurence Rodriguez as Chief Executive Officer
- : Gensight Biologics Secures €12 Million Financing Through A Premium Convertible Notes Issuance To An Institutional Investor And Provides Business Update
GenSight Biologics funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Post-IPO Equity | $1.0M |
| Mar 2026 | Post-IPO Equity | $1.7M |
| Nov 2025 | Funding Round | $2.0M |
| Jul 2025 | Seed | $500K |
| Dec 2022 | Convertible Note | $12.0M |
Leadership
- Clementine Ravache, CFO | Advisory & Interim Finance Roles
- Julio Benedicto, Vice President Marketing
- Laurence Rodriguez, Chief Executive Officer
- Scott Jeffers, Chief Technology Officer
- Jan Umiastowski, Chairman
- AG Medical Srl, Biomedical Engineer
- Agathe Ebongo, Consultante Assurance Qualité
Verified email and direct lines for GenSight Biologics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
GenSight Biologics in the news
- GenSight Biologics Announces the Closing of its €1.0 Million Fundraising Supported by Existing Shareholders - Yahoo Finance (Oct 16, 2026)
- GenSight Biologics Reports Cash Position as of September 30, 2026 - FinancialContent (Oct 07, 2026)
- GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates - Yahoo Finance (Sep 29, 2026)
- Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa - Business Wire (Oct 08, 2026)
- GenSight Biologics shares efficacy and safety findings from REFLECT Phase III gene therapy trial - Ophthalmology Times (Feb 18, 2025)
- GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates - Business Wire (Jul 08, 2026)
- France's GenSight Biologics H1 net loss widens on higher R&D expenses - TradingView (Sep 29, 2026)
- GenSight Biologics releases 1-year data from phase 1/2 trial of RP treatment - Glance by Eyes On Eyecare (Feb 16, 2023)
Companies similar to GenSight Biologics
- Tempest Therapeutics · Biopharma, Biotechnology, Health Care, Therapeutics
- BioLineRx Ltd · Biopharma, Biotechnology, Health Care, Therapeutics
- Cumulus Oncology · Biopharma, Biotechnology, Health Care, Therapeutics
- Sudo Biosciences · Biopharma, Biotechnology, Health Care, Therapeutics
- BerGenBio ASA · Biopharma, Biotechnology, Health Care, Therapeutics
About GenSight Biologics: questions and answers
What does GenSight Biologics do?
GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering
Where is GenSight Biologics headquartered?
GenSight Biologics is headquartered in Paris, France.
How many employees does GenSight Biologics have?
GenSight Biologics has about 26 employees.
Has GenSight Biologics raised funding?
Yes. Fundz has recorded 5 funding events for GenSight Biologics. The most recent, Post-IPO Equity of $1.0M, was in Oct 2026.
Who leads GenSight Biologics?
Julio Benedicto is a Vice President Marketing at GenSight Biologics.
What is the latest news on GenSight Biologics?
On Oct 16, 2026, GenSight Biologics has successfully completed a fundraising of €1 million, supported by existing shareholders.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy